Inside Global Pharma: Recent Episodes
ZS
Jennifer Curtis, Pranav Srivastava and Surbhi Puri discuss customer experience in cell and gene therapy (CGT), drawing on recent ZS patient experience study outcomes.
In this podcast, Jennifer Curtis and David Jackson share valuable insights on global commercial excellence. They highlight strategies to optimize product launches and maximize revenue potential based on recent research conducted by ZS on the top 25 pharma companies.Hosted by: Jennifer CurtisProduced by: Matilda Males & Sophie McManusFeaturing: David Jackson
In this episode, ZS leaders Jennifer Curtis, Pranav Srivastava and Surbhi Puri discuss customer experience in cell and gene therapy, drawing on recent ZS patient experience study outcomes.Hosted by: Jennifer CurtisProduced by: Matilda Males & Sophie McManusFeaturing: Pranav Srivastava and Surbhi Puri
In this episode, ZS leaders Jennifer Curtis, Pranav Srivastava and Surbhi Puri discuss customer experience in cell and gene therapy, drawing on recent ZS patient experience study outcomes.Hosed by: Jennifer CurtisProduced by: Matilda Males and Sophie McManusFeaturing: Pranav Srivastava and Surbhi Puri
Innovation is far more diffuse today, reflecting the increasingly fragmented nature of the pharma industry. On top of that, late-stage deals significantly underperform compared to early-stage strategy. So pharma may be in line for a shift in strategy. This edition of the “Inside Global Pharma” podcast features a discussion on an innovation constellation model, a focused and intentional strategy that emphasizes early-stage activity to drive long-term success.
ZS leaders Jennifer Curtis, Nan Wang and Cody Powers discuss how to drive stronger global strategy, focusing on the trends in in early- and late-stage pharma acquisitions explored in their recent research.Hosted by: Jennifer Curtis Produced by: Matilda Males & Sophie McManusFeaturing: Nan Wang and Cody Powers
On this episode of Inside Global Pharma, Jennifer Curtis and Maria Whitman discuss trends in global launches—from the drivers of commercial success to how companies can best map realistic opportunities for their pipeline assets. Listen to hear their predictions for what the future looks like including opportunities, challenges and priority areas to invest for success.
Highlights from the episode:
• Today, 40% of launches fail to meet expectations due to smaller and fragmented opportunities, increasing complexity of customer groups and global pharma’s more compressed resources
• Economic pressures and pipeline evolution from blockbusters to more targeted therapies necessitate a shift from traditional “command and control” to “needs-driven” launch models
• No-regret moves for pharma include making strategic decisions that balance short versus long-term capability development, focusing on customer needs, building digital capabilities and embracing more agile launch models
When most global pharmaceutical launches are as likely to underperform as overperform, how can leaders ensure they prepare their organizations for success? On this episode of Inside Global Pharma, ZS leaders Jennifer Curtis and Maria Whitman share their perspectives on the next era of global launch and where leaders should be investing to set up their organizations for success.
Be sure to also download the latest ZS podcast, Transforming Biopharma by ZS, hosted by Maria Whitman.
Additional Details https://www.pm360online.com/global-biopharma-launches-in-the-new-world-order/
Hosted by: Jennifer Curtis Produced by: Matilda Males & Sophie McManus Featuring: Maria Whitman
In this edition of the IGP podcast, Jennifer Curtis connects with Josh Hattem to discuss trends in oncology portfolio strategy, building on a previous IGP episode, “The value of focus.”
Highlights from the episode include:
· The oncology therapy area’s future is not as certain as it was in the past; blockbuster launches sold 47% higher on average in 2012-2016 compared to 2017-2021
· A range of factors contributed to this drop, including intense competition, smaller, more fragmented opportunities and the entrance of emerging pharma players into the space
· The latest ZS research suggests intentional use of the customer lens early in portfolio strategy development could help companies “win” in oncology by enhancing “share of mind”.
Listen to the podcast.
Jennifer Curtis connects with Ben Hohn to discuss trends in first launch and partnering, focusing on emerging pharma and changes in strategic decision-making.
Highlights from the episode include:
· Emerging pharma is driving industry innovation and a substantial share of total pharma pipeline
· Although Europe is typically considered a more challenging market, emerging pharma companies have seen success both in solo and partnered commercialization efforts
· This is partly due to ecosystem shifts, for example reduced reliance on acquisition by larger firms at the asset development stage, as well as an increased focus on specialist and orphan assets
Jennifer Curtis and Ben Hohn discuss trends in emerging pharma commercialization.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Ben Hohn
Jennifer Curtis and Ben Hohn discuss trends in emerging pharma commercialization.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Ben Hohn
In this edition, Jennifer Curtis connected with Hensley Evans and Tina Shepley to discuss the need for more market-shaping activities geared towards patients to ensure a successful product launch.
Highlights from the episode include:
· Activities that traditionally focus on HCPs and how patient-targeted campaigns are often “tick-the-box” exercises
· Pharma’s need to invest early and strategically to understand the patient experience and define engagement objectives
· Advice for manufacturers to go beyond the brand needs and understand patient needs in individual launch markets
Jennifer Curtis, Tina Shepley and Hensley Evans discuss the importance of patient centricity in market shaping for a successful product launch.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Hensley Evans and Tina Shepley
Jennifer Curtis and Jeffrey Moore discuss recent ZS insights and trends in #customerengagement
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Jeffrey Moore
The road to commercializing cell and gene therapies has been long, with many highs and lows along the way. However, the last few years have seen strong market growth and a very crowded pipeline. In this episode, ZS’s Jennifer Curtis and Sankalp Sethi discuss ongoing challenges and what it will take to successfully launch and commercialize these cutting-edge therapies in the U.S. and abroad.
The road to commercializing cell and gene therapies was long, but during the last years we have observed strong market growth and a very crowded pipeline. In this episode, we discuss more challenges and what it takes to successfully launch and commercialize these advanced therapies.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Sankalp Sethi
In light of World AIDS Day 2021, in this episode of ‘Inside Global Pharma’ we focus on the journey to eradicating AIDS and discuss themes of inequality today and how they can be managed.
Hosted by: Jennifer Curtis Produced by: Matilda Males and Sophie McManus Featuring: Mark Saunders and Bill Coyle
We immersed ourselves in R&D to discuss what drives clinical trial success beyond the science alone. Join us to learn what it means to be human-centric in the context of clinical trials, and how human-centric principles and cognitive science can aid trial recruitment and execution.
Hosted by: Jennifer Curtis Produced by: Matilda Males and Sophie McManus Featuring: Chris Crabtree and Jacob Braude
In this episode we are exploring the role of medical affairs in shaping stakeholder engagement strategies across both traditional and digital channels and what this means for the future of medical affairs.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Bora Erdemli and Sarah Jarvis
Customer engagement has been a hot topic across pharma med tech companies, even before the pandemic. In this episode, we discuss the future of customer engagement and how can companies deliver consistent, relevant, and positive experience in digital, in-person and hybrid world.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Jude Konzelmann and Heather Wiederholt
In this episode, our guest is Josh Hattem discussing insights from recent research on the value of focus in portfolio strategy for biopharmaceutical companies. Highlights from the episode include: - Defining what is a portfolio strategy within a biopharmaceutical company - Why focus can provide a competitive edge but companies often fail to maximize the benefits - Implications on how to align R&D and commercial strategy to drive pipeline investment and greater commercial success
Additional details – Article published on InVivo (March 2021) https://invivo.pharmaintelligence.informa.com/IV124716/The-Value-And-Challenge-Of-Focus-In-Pharma
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Joshua Hattem
COVID-19 has pushed the idea of scenario planning to the forefront. It is becoming increasingly important to be able to anticipate and plan for the unexpected by looking at the extremes, and how they could change the business. In this episode we focus on oncology and discuss three different worlds that could emerge in the future and implications on pharma’s business strategy.
Hosted by: Matilda Males Produced by: Matilda Males Featuring: Jennifer Curtis and Malik Kaman
Cancer has been progressively redefined over the past 20 years. One of the most active pipelines is immunotherapy, with almost 300 molecules in phase one or phase two trials. In this episode we are discussing if existing immunotherapies have lived up to the expectations and what will drive success for the next wave of products in this evolving market.
Hosted by: Jennifer Curtis Produced by: Matilda Males and Rohan Giblin Featuring: Malik Kaman, Jon Roffman, Sharon Karlsberg
COVID-19 has accelerated many trends that were only starting to emerge in healthcare before 2020. It led to an inflection point, bringing in new opportunities and challenges in how pharma and medtech companies serve patients and other customers. Here, we set to explore COVID-19 not just as a unique event and implications specific to it, but more as the wider trends we anticipate playing out and how pharma and medtech companies need to prepare and invest to win in the future.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Brian Chapman, David Jackson, Mark Saunders
Patient centricity is a topic that has been floating around healthcare organizations for the better part of the last decade. Most healthcare companies have something about patients in their mission statement or vision. However, although the patients are the ultimate customers in the healthcare landscape, they may not always be in the forefront. In this episode we talk with two ZS leaders to hear their perspective on what patient centricity really means and what organizations can do today to become more patient centric.
Hosted by: Jennifer Curtis Produced by: Matilda Males and Rohan Giblin Featuring: Hensley Evans, Gordon Bache
The oncology pharmaceutical landscape is exploding – both in revenue and competition. Integrated, customer-centric brand strategies provide an opportunity to stand out from the competition by delivering more customer value. Our host, Jennifer Curtis, a leader in our European Marketing Practice, speaks with leaders in ZS’ oncology, marketing and market access practices to identify the key success factors in delivering a customer-centric global brand strategy.
Hosted by: Jennifer Curtis Produced by: Matilda Males and Rohan Giblin Featuring: Malik Kaman, Kurt Kessler, Smita Sealey
Over the last decade the combination of high unmet patient need and revenue potential has resulted in companies of all sizes moving into the Oncology space. Now competition is fierce and the pathway to success has many obstacles. There are more and more “me-too”, less clinically differentiated assets competing the same space with high prices. So, what is a pharma company to do when talking about the data is just not enough to win? In this podcast three ZS experts share insights on how to compete in this landscape.
Hosted by: Jennifer Curtis Produced by: Matilda Males Featuring: Pranav Srivastava, Bill Coyle, Falko Graf-Meisner